Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Three new biologic agents help drive five percent annual growth in ulcerative colitis drug market

Decision Resources : 14 August, 2008  (Company News)
Decision Resources anticipates five percent annual growth through 2017 in the ulcerative colitis drug market will be driven by strong uptake of Abbott/Eisai's Humira, Centocor/Schering-Plough/Mitsubishi Tanabe Pharma/Janssen's golimumab and Bristol-Myers Squibb's Orencia, following the expected approvals and launches of these three biologic agents for ulcerative colitis by 2017.
The new Decision Resources’ Pharmacor report entitled ‘Ulcerative Colitis’ finds that Humira and golimumab - as maintenance therapies - will drive nearly two-thirds of the growth in the ulcerative colitis market in the USA, France, Germany, Italy, Spain and the United Kingdom over the next ten years.

Humira and golimumab will expand treatment options for moderate to severe patients who fail treatment with conventional pharmacotherapies, posing a threat to Centocor/Schering-Plough/Mitsubishi Tanabe Pharma's Remicade. Additionally, the approval of Orencia by 2012 for the treatment of moderate to severe disease as an acute and maintenance therapy, will expand treatment options for patients who fail treatment with tumor necrosis factor-alpha (TNF-alpha) inhibitors.

'We project golimumab may have an advantage over its predecessors within the TNF-alpha inhibitor class-specifically Remicade and Humira-because the drug is being investigated for both intravenous and subcutaneous delivery,' said Kathryn Benton, analyst at Decision Resources. 'However, we expect Humira to outperform golimumab in ulcerative colitis sales due to Humira's earlier market entry and more well-established long-term safety profile.'

The report also finds that the uptake of Shire/Takeda/Giuliani's Lialda/Mezavant/Mezavant XL and its launch in additional countries will contribute to market growth, owing to the agent's improved dosing convenience and its premium price compared to currently marketed drugs in its class. Lialda/Mezavant/Mezavant XL, the most recently approved oral 5- aminosalicylate, has launched in the USA, Germany and the United Kingdom and is expected to launch in the remaining European markets in late 2008.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   Â© 2012 ProHealthServiceZone.com
Netgains Logo